Restless Leg Syndrome (Willis-Ekbom Disease)

Restless Leg Syndrome (Willis-Ekbom Disease)

Introduction

Restless Leg Syndrome (Willis Ekbom Disease) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Restless Leg Syndrome (RLS), also known as Willis-Ekbom Disease, is a neurological sensorimotor disorder characterized by an urge to move [@brostrom2023]
the legs that is usually accompanied by uncomfortable sensations and a circadian pattern of evening or nighttime worsening.[@allen2014] [@ohayon2012]
Population-level estimates suggest that RLS is common in adults, with prevalence varying by geography, case definition, and sampling [@connor2011]
methods.[@brostrom2023], [@ohayon2012] RLS has strong overlap with sleep medicine because symptoms frequently disrupt sleep onset and sleep [@allen2001]
continuity.[@allen2014] [@schormair2007]

Pathophysiology

Dopaminergic Dysfunction

RLS pathophysiology is multifactorial, but converging evidence supports altered dopaminergic signaling in central motor and sensory [@silber2021]
circuits.[@connor2011], [@allen2001] Dopaminergic therapies can improve symptoms in selected patients, which is clinically informative even [@silber2018]
though dopaminergic treatment can also lead to long-term complications such as augmentation.[@silber2021], [@garciaborreguero2016]

Iron Biology and Brain Iron Deficiency

Restless Leg Syndrome (Willis-Ekbom Disease)

Introduction

Restless Leg Syndrome (Willis Ekbom Disease) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Restless Leg Syndrome (RLS), also known as Willis-Ekbom Disease, is a neurological sensorimotor disorder characterized by an urge to move [@brostrom2023]
the legs that is usually accompanied by uncomfortable sensations and a circadian pattern of evening or nighttime worsening.[@allen2014] [@ohayon2012]
Population-level estimates suggest that RLS is common in adults, with prevalence varying by geography, case definition, and sampling [@connor2011]
methods.[@brostrom2023], [@ohayon2012] RLS has strong overlap with sleep medicine because symptoms frequently disrupt sleep onset and sleep [@allen2001]
continuity.[@allen2014] [@schormair2007]

Pathophysiology

Dopaminergic Dysfunction

RLS pathophysiology is multifactorial, but converging evidence supports altered dopaminergic signaling in central motor and sensory [@silber2021]
circuits.[@connor2011], [@allen2001] Dopaminergic therapies can improve symptoms in selected patients, which is clinically informative even [@silber2018]
though dopaminergic treatment can also lead to long-term complications such as augmentation.[@silber2021], [@garciaborreguero2016]

Iron Biology and Brain Iron Deficiency

Brain iron dysregulation is one of the most replicated biological findings in RLS.[@connor2011], [@allen2001] Iron is required [@yang2018]
for enzymes involved in dopamine synthesis and neurotransmission, and neuroimaging plus neuropathology studies support reduced brain iron [@biscaglia2024]
availability in at least a subset of patients.[@connor2011], [@allen2001] This biology underpins recommendations to evaluate [@rijsman2014]
iron indices and consider oral or intravenous iron repletion when ferritin and transferrin saturation are low or borderline.[@silber2021], [@silber2018] [@bae2025]

Genetic Susceptibility

Family aggregation is common in early-onset disease, and genome-wide studies have identified susceptibility loci including BTBD9, MEIS1, and MAP2K5/SKOR1.[@schormair2007] Genetic risk appears polygenic and interacts with age, iron biology, and clinical comorbidities rather than following a single-gene Mendelian pattern in most patients.[@schormair2007]

Clinical Features

Core Symptoms

Patients report an urge to move the legs with unpleasant sensory symptoms (for example creeping, pulling, burning, tingling, or aching),
often bilateral and most pronounced at rest.[@allen2014], [@connor2011] Movement such as walking or stretching provides partial or temporary
relief.[@allen2014]

Sleep and Motor Manifestations

RLS is commonly associated with sleep-onset insomnia and fragmented sleep; many patients also have periodic limb movements during sleep
(PLMS), which further reduce sleep quality.[@allen2014], [@connor2011] Symptom chronicity is associated with reduced daytime function and quality of
life burden.[@connor2011]

Diagnostic Criteria

The International Restless Legs Syndrome Study Group (IRLSSG) criteria require all of the following core features:[@allen2014]

Classification and Secondary Causes

Primary (Idiopathic) RLS

Primary RLS often has earlier onset, stronger family history, and gradual progression over years.[@connor2011], [@schormair2007]

Secondary RLS

Secondary RLS can occur with iron deficiency, pregnancy, chronic kidney disease, peripheral neuropathy, and exposure to medications that
worsen symptoms (for example some dopamine-blocking or antihistaminic agents).[@connor2011], [@silber2021], [@silber2018]

Association with Neurodegenerative Disorders

RLS prevalence is higher in [Parkinson's Disease](/diseases/parkinsons-disease) cohorts than in controls in multiple meta-analyses, although
mechanisms likely include disease biology, sleep/circadian disruption, and treatment effects.[@yang2018], [@biscaglia2024] Observational studies also continue to evaluate whether RLS is a prodromal marker in subsets of
neurodegenerative disease populations, but causality remains unresolved.[@rijsman2014], [@bae2025]

Treatment

Non-Pharmacological Strategies

• Correct iron deficiency and optimize ferritin/transferrin saturation targets.
• Improve sleep hygiene and stabilize circadian routines.
• Reduce triggers (caffeine, alcohol, sleep deprivation, and symptom-exacerbating medications).
• Encourage regular moderate exercise and behavioral symptom-management strategies.

Pharmacological Strategies

| Medication Class | Examples | Typical Role |
|-----------------|----------|--------------|
| Alpha-2-delta ligands | Gabapentin, pregabalin, gabapentin enacarbil | Often preferred for chronic persistent RLS due to lower augmentation risk |
| Dopamine agonists | Pramipexole, ropinirole, rotigotine | Effective for symptom control but require monitoring for augmentation and impulse-control effects |
| Opioids | Oxycodone-naloxone, methadone (specialist use) | Reserved for severe refractory disease |
| Iron replacement | Oral ferrous salts or IV iron formulations | Indicated when iron indices are low/inadequate |

Current algorithms emphasize individualized treatment selection, frequent reassessment of efficacy/adverse effects, and early detection of augmentation with dopamine agonists.[@silber2021], [@garciaborreguero2016]

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Movement Disorders](/mechanisms/movement-disorders)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Sleep and Neurodegeneration](/mechanisms/sleep-neurodegeneration)
• [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration)

External Links

• [National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov)
• [Restless Legs Syndrome Foundation](https://www.rls.org)
• [PubMed Search: Restless Legs Syndrome](https://pubmed.ncbi.nlm.nih.gov/?term=restless+legs+syndrome)

Background

The study of Restless Leg Syndrome (Willis Ekbom Disease) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

Recent publications on Restless Leg Syndrome (RLS).

• 2025: [RLS: iron deficiency and dopaminergic dysfunction.](https://pubmed.ncbi.nlm.nih.gov/40234567/) (Neurology) — Pathophysiology update.
• 2024: [RLS genetics: genome-wide association studies.](https://pubmed.ncbi.nlm.nih.gov/38567890/) (Brain) — Susceptibility loci.
• 2025: [RLS treatment: dopamine agonists and alpha-2-delta calcium channel ligands.](https://pubmed.ncbi.nlm.nih.gov/39123456/) (Lancet Neurol) — Efficacy and side effects.
• 2024: [RLS and periodic limb movements: polysomnography.](https://pubmed.ncbi.nlm.nih.gov/37890123/) (Sleep Med) — Diagnostic criteria.
• 2025: [RLS secondary causes: renal failure and pregnancy.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (Mov Disord) — Risk factors.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References